Abstract:During the past decade we have witnessed a number of changes in the field of non-Hodgkin lymphoma (NHL), including new entities added to the classification as well as a better understanding of the biology of diffuse large B-cell lymphoma (DLBCL). An understanding of the epigenetics of NHL is also contributing new agents for the management of this disorder. It has become increasingly clear that DLBCL is a biologically and clinically heterogeneous cell type. Two major categories are now recognized: germinal center B cell and activated B-cell (ABC) types. The former is associated with a good prognosis while the latter is known to have a more adverse outcome. With the use of routine immunohistochemical stains, these two types can be identified. The ABC type is known to be NFK-B dependent. NFK-B is a therapeutic target for bortezomib which is being investigated as treatment for this subtype of DLBCL. Several major changes in the classification will be discussed among which the most important are the recognition of so-called borderline entities. One of the two most common of these is the borderline DLBCL/Burkitt tumor (DLBCL/BL) which has features of both DLBCL and Burkitt's lymphoma. Many of the cases in this DLBCL/BL category contain a translocation of MYC as well as BCL2, so-called "double-hit lymphomas" which have a very aggressive clinical behavior. The second common borderline entity is the mediastinal grey zone NHL (MGZL) which has pathological features intermediate between primary mediastinal B-cell lymphoma and nodular sclerosing Hodgkin lymphoma (NSHL). Overlapping clinical features include young age, male predominance, and localized mediastinal presentation. Anecdotal reports suggest MGZL is relatively resistant to Hodgkin-based chemotherapy. Epigenetic therapy represents a new concept. Histone deacetylase inhibitors (HDACi)and DNA methyltransferase inhibitors constitute a promising new class of antineoplastic agents. They modify the expression of genes related to cancer development. In this review, we discuss the role of HDACi in lymphomagenesis as well as in treatment. To understand the benefits of HDACi in lymphoma treatment, we must appreciate the crucial interplay between BCL6, p53, and STAT3. The STAT3 oncogene is involved in the ABC type of DLBCL, an unfavorable and frequently therapy-refractory lymphoma. STAT3 can be effectively suppressed by several HDACi. We will summarize the results of recent trials with HDACi such as romidepsin, panobinostat and valproic acid that have shown significant preliminary activity in recurrent and refractory lymphomas. Their future role in front-line management remains to be determined.

Research Progress of T Cell Lymphoma: Reports from 2014 International Conference on T Cell Lymphoma in Clinical Treatment

Research Progress in Treatment of Peripheral T-cell Lymphoma

Progress in Treatment of Relapsed/refractory Peripheral T-cell Lymphoma

Research Progress of Primary Testicular Lymphoma and Primary Central Nervous System Lymphoma: Reports from the 19th European Hematology Association Annual Congress

SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

[Progress in the treatment of mature T-cell lymphoma]

Updates in the Treatment of Peripheral T-Cell Lymphomas

Epigenetic targets in B- and T-cell lymphomas: latest developments

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma

[Current standard in diagnostic and therapy of peripheral T-cell lymphoma]

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Non-Hodgkin's lymphoma: the old and the new

New insights into the biology of T-cell lymphomas

Immune Checkpoint Inhibitors And Cellular Treatment For Lymphoma Immunotherapy

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

[Recent advances in the treatment of DLBCL]

[Analysis of Clinical Feature and Curative Efficacy of 30 Patients with T Cell Lymphoblastic Lymphoma].

Research Progress of Hodgkin Lymphoma